Despite lots of positive vibes among shareholders, I'm not too impressed at all with this and not sure why it is deemed price sensitive. There are so many unknowns stated in this announcement its ridiculous (highlighted in yellow). This trial will take at least 2-3 years to conclude to the primary endpoint from now.
This announcement shows nothing but uncertainty, and it may as well say nothing at all. I'll keep a watch from the sidelines for now but may consider re-entering a position under $1 should it eventuate. Good luck to all holders.
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain, page-130
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.030(2.84%) |
Mkt cap ! $1.187B | |||
| Open | High | Low | Value | Volume |
| $1.06 | $1.06 | $1.02 | $1.336M | 1.284M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 69751 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 14603 | 7 |
View Market Depth
| Last trade - 15.37pm 25/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |